Literature DB >> 8204312

Bronchospasm induced by intravenous adenosine.

I Drake1, P A Routledge, R Richards.   

Abstract

1. Adenosine is well known to cause bronchoconstriction when inhaled, but to date, there has been only one report following the intravenous route. 2. Adenosine caused bronchoconstriction in two patients (the only two with asthma) out of 26 treated with the drug. In one subject the duration of response was much longer than previously reported following inhalation. 3. We suggest that adenosine may aggravate bronchospasm in some asthmatics and alternative treatments for supraventricular tachycardia should be considered in this group.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204312     DOI: 10.1177/096032719401300407

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  9 in total

1.  Intracellular adenosine inhibits IgE-dependent degranulation of human skin mast cells.

Authors:  Gregorio Gomez; Vincent Nardone; Sahar Lotfi-Emran; Wei Zhao; Lawrence B Schwartz
Journal:  J Clin Immunol       Date:  2013-11       Impact factor: 8.317

2.  Respiratory arrest during dipyridamole stress testing.

Authors:  G S Hillis; A al-Mohammad; K P Jennings
Journal:  Postgrad Med J       Date:  1997-05       Impact factor: 2.401

3.  Long-Term Evolution of Patients Treated for Paroxysmal Atrial Fibrillation with First and Second Generation Cryoballoon Catheter Ablation with a Prospective Protocol Guided by Complete Bidirectional Left Atrium-Pulmonary Veins Disconnection after Adenosine as Main Target end Point to achieved. Seven Years Follow-up of Patients with a rough estimation profile of Low ALARMEc Score. A Single Center Report.

Authors:  Jesus M Paylos; Aracelis Morales; Luis Azcona; Marisol Paradela; Raquel Yagüe; Fernando Gómez-Guijarro; Lourdes Lacal; R N Clara Ferrero; Octavio Rodríguez
Journal:  J Atr Fibrillation       Date:  2016-04-30

4.  Disparity in FcεRI-induced degranulation of primary human lung and skin mast cells exposed to adenosine.

Authors:  Gregorio Gomez; Wei Zhao; Lawrence B Schwartz
Journal:  J Clin Immunol       Date:  2011-03-25       Impact factor: 8.317

5.  Effect of adenosine infusion on oxygen induced carbon dioxide retention in severe chronic obstructive pulmonary disease.

Authors:  T L Griffiths; S S Fernando; K B Saunders
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

6.  Effects of propofol and ketamine on ATP-induced contraction of the rat trachea.

Authors:  Masakazu Yamaguchi; Osamu Shibata; Masataka Saito; Maki Yoshimura; Kenji Nishioka; Tetsuji Makita; Koji Sumikawa
Journal:  J Anesth       Date:  2007-01-30       Impact factor: 2.078

7.  Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

8.  Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial).

Authors:  Gregory S Thomas; Bruce R Tammelin; George L Schiffman; Rudy Marquez; Deborah L Rice; Douglas Milikien; Vandana Mathur
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

Review 9.  AMP deaminase 1 gene polymorphism and heart disease-a genetic association that highlights new treatment.

Authors:  Ryszard T Smolenski; Iwona Rybakowska; Jacek Turyn; Paweł Romaszko; Magdalena Zabielska; Anne Taegtmeyer; Ewa M Słomińska; Krystian K Kaletha; Paul J R Barton
Journal:  Cardiovasc Drugs Ther       Date:  2014-04       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.